Clinical Trial Update: Safety, Tolerability and Efficacy of S-1226 in Post-COVID-19 Subjects With Persistent Respiratory Symptoms. [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating safety, tolerability and efficacy of S-1226 in adults with persistent respiratory symptoms after COVID-19 (Post-Acute Sequelae…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Respiratory Symptoms
• Long Covid
• Post-acute Sequelae of Sars-cov-2 Infection

Drugs mentioned

• S-1226

Snippet

Sponsor: SolAeroMed Inc. | Conditions: Post Acute COVID-19 Syndrome, Long COVID | Phase 2 | Status: UNKNOWN